دورية أكاديمية
Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.
| العنوان: | Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring. |
|---|---|
| المؤلفون: | Yang J; Department of Clinical laboratory, Fourth People’s Hospital of Jinan, Jinan 250031, China., Lin N; Department of Clinical laboratory, Fourth People’s Hospital of Jinan, Jinan 250031, China., Niu M; Department of Clinical laboratory, Fourth People’s Hospital of Jinan, Jinan 250031, China., Yin B; Department of Clinical laboratory, Fourth People’s Hospital of Jinan, Jinan 250031, China. |
| المصدر: | Aging [Aging (Albany NY)] 2024 Jul 19; Vol. 16 (14), pp. 11460-11474. Date of Electronic Publication: 2024 Jul 19. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, NY : Impact Journals, LLC |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/diagnosis , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/blood , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/genetics , Liver Neoplasms*/diagnosis , Liver Neoplasms*/blood , Liver Neoplasms*/therapy , Liver Neoplasms*/pathology , Circulating Tumor DNA*/genetics , Circulating Tumor DNA*/blood , Early Detection of Cancer*/methods , Biomarkers, Tumor*/genetics , Biomarkers, Tumor*/blood, Humans ; DNA Mutational Analysis/methods ; Mutation ; Liquid Biopsy/methods |
| مستخلص: | In recent years, the detection and analysis of circulating tumor DNA (ctDNA) have emerged as a new focus in the field of cancer research, particularly in the early diagnosis of hepatocellular carcinoma (HCC) and monitoring of therapeutic efficacy. ctDNA, which refers to cell-free DNA fragments released into the bloodstream from tumor cells upon cell death or shedding, carries tumor-specific genetic and epigenetic alterations, thereby providing a non-invasive approach for cancer diagnosis and prognosis. The concentration of ctDNA in the blood is higher compared to that in healthy individuals or other liquid biopsies from early-stage cancers, which is closely associated with the early diagnosis and comprehensive sequencing studies of HCC. Recent studies have indicated that sequential ctDNA analysis in patients receiving primary or adjuvant therapy for HCC can detect treatment resistance and recurrence before visible morphological changes in the tumor, making it a valuable basis for rapid adjustment of treatment strategies. However, this technology is continuously being optimized and improved. Challenges such as enhancing the accuracy of ctDNA sequencing tests, reducing the burden of high-throughput sequencing on a large number of samples, and controlling variables in the assessment of the relationship between ctDNA concentration and tumor burden, need to be addressed. Overall, despite the existing challenges, the examination and analysis of ctDNA have opened up new avenues for early diagnosis and therapeutic efficacy monitoring in hepatocellular carcinoma, expanding the horizons of this field. |
| References: | J Exp Clin Cancer Res. 2022 Jan 3;41(1):3. (PMID: 34980204) PLoS One. 2018 Mar 16;13(3):e0194630. (PMID: 29547634) Transl Oncol. 2021 Jul;14(7):101073. (PMID: 33915518) Lancet. 2018 Mar 31;391(10127):1301-1314. (PMID: 29307467) Cell Mol Gastroenterol Hepatol. 2022;13(6):1611-1624. (PMID: 35183803) Ann Oncol. 2018 May 1;29(5):1286-1291. (PMID: 29509837) Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534. (PMID: 28210698) Cancers (Basel). 2021 Nov 14;13(22):. (PMID: 34830853) Cancers (Basel). 2022 Sep 01;14(17):. (PMID: 36077815) Cancers (Basel). 2022 Jun 23;14(13):. (PMID: 35804850) Clin Chem. 2022 Jul 3;68(7):940-952. (PMID: 35687601) World J Gastroenterol. 2021 Aug 28;27(32):5341-5350. (PMID: 34539136) Clin Liver Dis. 2023 Feb;27(1):85-102. (PMID: 36400469) Oncotarget. 2017 May 16;8(20):33614-33620. (PMID: 28431395) Theranostics. 2019 Apr 6;9(7):2056-2070. (PMID: 31037156) Nat Rev Clin Oncol. 2022 Sep;19(9):600-612. (PMID: 35915225) Am Soc Clin Oncol Educ Book. 2018 May 23;38:964-977. (PMID: 30231325) J Cancer Res Clin Oncol. 2018 Nov;144(11):2167-2175. (PMID: 30203147) Cancers (Basel). 2022 Dec 07;14(24):. (PMID: 36551512) Cell Biosci. 2016 May 11;6:32. (PMID: 27182434) Biosens Bioelectron. 2015 May 15;67:443-9. (PMID: 25220802) ACS Sens. 2018 Mar 23;3(3):540-560. (PMID: 29441780) J Biol Inorg Chem. 2005 Nov;10(7):790-9. (PMID: 16208493) Front Genet. 2023 Aug 01;14:1235260. (PMID: 37593116) Nat Cancer. 2020 Mar;1(3):276-290. (PMID: 35122035) Diagnostics (Basel). 2023 Feb 11;13(4):. (PMID: 36832164) Sci Transl Med. 2018 Nov 7;10(466):. (PMID: 30404863) Expert Rev Mol Diagn. 2022 May;22(5):507-518. (PMID: 35758097) Nat Cancer. 2020 Sep;1(9):873-881. (PMID: 35121950) Transl Oncol. 2022 Jan;15(1):101279. (PMID: 34800919) Mol Cancer Ther. 2021 Dec;20(12):2577-2584. (PMID: 34518295) Exp Mol Med. 2018 Oct 12;50(10):1-9. (PMID: 30315182) Biosens Bioelectron. 2023 Dec 1;241:115721. (PMID: 37788579) Sci Rep. 2021 Jul 22;11(1):14999. (PMID: 34294857) Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. (PMID: 29950351) Cancers (Basel). 2021 May 10;13(9):. (PMID: 34068786) Expert Rev Mol Diagn. 2019 Feb;19(2):121-135. (PMID: 30648442) Lancet Gastroenterol Hepatol. 2023 Sep;8(9):837-852. (PMID: 37499673) Clin Chim Acta. 2024 Jan 1;552:117673. (PMID: 38007055) Biomark Med. 2018 Nov;12(11):1197-1201. (PMID: 30379093) Clin Cancer Res. 2019 Oct 15;25(20):6107-6118. (PMID: 31363003) Int J Cancer. 2019 Jul 15;145(2):540-547. (PMID: 30628066) Int J Mol Sci. 2022 Aug 12;23(16):. (PMID: 36012272) Br J Cancer. 1997;76(5):628-33. (PMID: 9303362) Ann Oncol. 2019 Nov 1;30(11):1804-1812. (PMID: 31562764) Anal Chem. 2022 Feb 22;94(7):3386-3393. (PMID: 35143161) Expert Rev Mol Diagn. 2021 Jan;21(1):3-15. (PMID: 33305634) Expert Rev Mol Diagn. 2018 Jan;18(1):7-17. (PMID: 29115895) Clin Exp Med. 2018 Aug;18(3):421-431. (PMID: 29749584) Cell. 2024 Mar 28;187(7):1589-1616. (PMID: 38552609) Biotech Histochem. 2021 Jul;96(5):376-383. (PMID: 32876508) J Exp Clin Cancer Res. 2021 Jun 26;40(1):215. (PMID: 34174931) Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):670-681. (PMID: 35676420) Heliyon. 2023 Mar 08;9(3):e14307. (PMID: 36950649) J Hematol Oncol. 2022 Sep 12;15(1):131. (PMID: 36096847) World J Gastroenterol. 2015 Sep 14;21(34):9853-62. (PMID: 26379392) Front Immunol. 2021 Oct 28;12:759565. (PMID: 34777372) Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385) Clin Chem. 2024 Jan 4;70(1):33-48. (PMID: 37962158) Cancer Biol Ther. 2022 Dec 31;23(1):439-445. (PMID: 35921289) Yonsei Med J. 2018 Jun;59(4):470-479. (PMID: 29749129) J Clin Invest. 2022 Jun 15;132(12):. (PMID: 35703177) Cancers (Basel). 2020 Sep 29;12(10):. (PMID: 33003583) J Gastroenterol Hepatol. 2021 Apr;36(4):1118-1125. (PMID: 32830343) Oncogene. 2018 Jul;37(27):3740-3752. (PMID: 29628508) Biosens Bioelectron. 2019 Apr 1;130:236-244. (PMID: 30769288) Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209-15. (PMID: 22594497) NPJ Breast Cancer. 2021 Mar 25;7(1):32. (PMID: 33767190) Biosci Trends. 2021 Jul 6;15(3):155-160. (PMID: 34039818) Int J Biol Sci. 2020 Mar 5;16(9):1551-1562. (PMID: 32226301) Hepatology. 2008 May;47(5):1437-45. (PMID: 18393287) Scand J Gastroenterol. 2020 Dec;55(12):1433-1440. (PMID: 33103505) Int J Cancer. 2017 Sep 1;141(5):977-985. (PMID: 28543104) Genes Genomics. 2023 Aug;45(8):1037-1046. (PMID: 37306927) Life (Basel). 2021 Aug 28;11(9):. (PMID: 34575039) Cancer Genomics Proteomics. 2021 May-Jun;18(3 Suppl):369-383. (PMID: 33994362) Clin Cancer Res. 2019 Sep 1;25(17):5284-5294. (PMID: 31217202) J Thorac Oncol. 2023 Nov;18(11):1581-1593. (PMID: 37541389) PLoS One. 2017 Aug 10;12(8):e0182562. (PMID: 28796802) Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314. (PMID: 31682895) Crit Rev Clin Lab Sci. 2020 Jan;57(1):54-72. (PMID: 31674269) Clin Cancer Res. 2023 Jan 17;29(2):302-304. (PMID: 36378102) Eur J Radiol. 2018 Apr;101:72-81. (PMID: 29571804) Lancet. 2022 Oct 15;400(10360):1345-1362. (PMID: 36084663) Front Med (Lausanne). 2018 Mar 26;5:78. (PMID: 29632864) Clin Cancer Res. 2021 Jun 1;27(11):3094-3105. (PMID: 33558422) PLoS One. 2016 Sep 14;11(9):e0162809. (PMID: 27626278) J Am Chem Soc. 2016 Aug 31;138(34):11009-16. (PMID: 27513828) Sci Transl Med. 2012 May 30;4(136):136ra68. (PMID: 22649089) Signal Transduct Target Ther. 2020 Jun 10;5(1):87. (PMID: 32532960) Front Oncol. 2023 Mar 07;13:1119744. (PMID: 36959801) Nat Commun. 2021 Jan 4;12(1):11. (PMID: 33397889) Clin Chem. 2008 Sep;54(9):1528-36. (PMID: 18653827) BMC Cancer. 2021 Apr 8;21(1):376. (PMID: 33827453) Nat Mater. 2017 Nov;16(11):1155-1161. (PMID: 29035356) Brief Bioinform. 2021 May 20;22(3):. (PMID: 32789496) |
| فهرسة مساهمة: | Keywords: circulating tumor DNA; early diagnosis; hepatocellular carcinoma; high-throughput sequencing; therapeutic efficacy monitoring |
| المشرفين على المادة: | 0 (Circulating Tumor DNA) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20240721 Date Completed: 20240805 Latest Revision: 20240811 |
| رمز التحديث: | 20240812 |
| مُعرف محوري في PubMed: | PMC11315387 |
| DOI: | 10.18632/aging.205980 |
| PMID: | 39033781 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1945-4589 |
|---|---|
| DOI: | 10.18632/aging.205980 |